Page last updated: 2024-08-26

prolinedithiocarbamate and Lupus Erythematosus, Systemic

prolinedithiocarbamate has been researched along with Lupus Erythematosus, Systemic in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, H; Chen, J; Geng, L; Hou, Y; Li, X; Lu, L; Shi, S; Sun, L; Tang, Y; Xie, H; Zeng, X1

Trials

1 trial(s) available for prolinedithiocarbamate and Lupus Erythematosus, Systemic

ArticleYear
Activated NF-κB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling.
    Stem cells and development, 2013, Feb-15, Volume: 22, Issue:4

    Topics: Adult; Antineoplastic Agents; Bone Marrow Cells; Bone Morphogenetic Protein 2; Cell Differentiation; Cells, Cultured; Down-Regulation; Female; Humans; Lupus Erythematosus, Systemic; Male; Mesenchymal Stem Cells; Middle Aged; NF-kappa B; Osteoblasts; Osteogenesis; Phosphorylation; Proline; Signal Transduction; Smad Proteins; Thiocarbamates; Tumor Necrosis Factor-alpha

2013